Septerna Q3 2026 Results: Net Loss of $26.6M
Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery using its Native Complex Platform. As of November 4, 2026, the company had 47,549,223 shares of common stock outstanding and is classified as an emerging growth company and non-accelerated filer.
- Key figure
- Net loss $26.6M